Congress Asset Management CO Mirati Therapeutics, Inc. Transaction History

Congress Asset Management CO

  • $14.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 01, 2023
BUY
$27.8 - $45.35 $1,362 - $2,222
49 Added 0.14%
35,509 $1.55 Million
Q2 2023

Jul 27, 2023
BUY
$36.13 - $49.49 $17,089 - $23,408
473 Added 1.35%
35,460 $1.28 Million
Q1 2023

Apr 21, 2023
BUY
$36.54 - $54.26 $1.28 Million - $1.9 Million
34,987 New
34,987 $1.3 Million

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Congress Asset Management CO Portfolio

Follow Congress Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Congress Asset Management CO , based on Form 13F filings with the SEC.

News

Stay updated on Congress Asset Management CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email